A multicenter, real-world, observational study showed safety and efficacy of a fixed-dose combination of preservative-free tafluprost and timolol in clinical practice. Patients who did not sufficiently respond to previous therapies achieved significant IOP reduction at 6 months, with the added benefit of decreased ocular surface side effects.
The VISIONARY study included 577 patients with open-angle glaucoma or ocular hypertension who did not respond or were not tolerant to monotherapy with beta-blockers or prostaglandin analogues. Patients were switched to single daily administration of the
Uncategorized